SPOTLIGHT -
Slideshow
Author(s):
Among the clues revealed in 3 recent studies: brain amyloid, saliva biomarkers, and microvascular dysfunction.
January in Review: Updates on the Psychiatric Treatment Pipeline
What Will the Future of Alzheimer Disease Treatment Look Like?
FDA Accepts Biologics License Application for Lecanemab-irmb
Diagnosis and Treatment of Depressive and Memory Problems in Older Adults
FDA Grants Fast Track Designation to Posdinemab for Early Alzheimer Disease
Therapeutic Advances in Alzheimer Disease